Posted by Michael Wonder on 01 Apr 2025
Tivdak (tisotumab vedotin) approved by European Commission for previously treated recurrent or metastatic cervical cancer
31 March 2025 - In the global Phase 3 innovaTV 301 clinical trial Tivdak demonstrated superior overall survival compared to chemotherapy.
Genmab announced today that the European Commission has granted marketing authorisation for Tivdak (tisotumab vedotin), an antibody drug conjugate, as monotherapy treatment for adult patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.
